Foghorn Therapeutics Inc.
FHTX
$4.57
-$0.015-0.33%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -63.42% | 13.36% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -63.42% | 13.36% | |||
| Cost of Revenue | 7,119.68% | -- | |||
| Gross Profit | -1,439.10% | -4.86% | |||
| SG&A Expenses | -8.87% | -4.83% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.16% | 1.73% | |||
| Operating Income | -0.64% | 1.58% | |||
| Income Before Tax | -1.99% | 16.78% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1.99% | 16.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.99% | 16.78% | |||
| EBIT | -0.64% | 1.58% | |||
| EBITDA | -0.54% | 1.38% | |||
| EPS Basic | -1.57% | 31.45% | |||
| Normalized Basic EPS | -1.57% | 23.46% | |||
| EPS Diluted | -1.57% | 31.45% | |||
| Normalized Diluted EPS | -1.57% | 23.46% | |||
| Average Basic Shares Outstanding | 0.43% | 21.37% | |||
| Average Diluted Shares Outstanding | 0.43% | 21.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
